Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Goat serum-derived polyclonal antibodies

Drug Profile

Goat serum-derived polyclonal antibodies

Alternative Names: Aimspro; Caprine hyperimmune serum; Caprivax; Ceremben; Goat serum derived product; HICS; Hyperimmune caprine serum; Hyperimmune goat serum product

Latest Information Update: 23 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daval International
  • Class Immunoglobulins; Polyclonal antibodies; Serum globulins
  • Mechanism of Action Corticotropin-releasing hormone stimulants; Immunomodulators; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Amyotrophic lateral sclerosis; Globoid cell leukodystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Multiple sclerosis; Systemic scleroderma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Jun 2015 Aimspro® is still in active development for Amyotrophic lateral sclerosis in Australia and United Kingdom
  • 23 Jun 2015 Aimspro® is still in active development for Multiple sclerosis and Systemic scleroderma in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top